COR Therapeutics, Inc. Files for Stock Offering

Business Wire, Sept 8, 1997

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sept. 8, 1997-- COR Therapeutics, Inc. (Nasdaq: CORR) announced that it has filed a registration statement with the Securities and Exchange Commission for a public offering of 2,500,000 newly issued shares of Common Stock (not including 375,000 shares issuable on exercise of the Underwriters' over-allotment option). All of the shares are being offered by the Company. The offering is being underwritten by Robertson, Stephens & Company LLC and Hambrecht & Quist LLC.

COR Therapeutics, Inc. is dedicated to the discovery, development and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases. COR has complementary product research and development programs that seek to address critical needs in severe cardiovascular care, including unstable angina, acute myocardial infarction, deep vein thrombosis and restenosis.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A copy of the preliminary prospectus relating to these securities may be obtained from Robertson, Stephens & Company LLC at 555 California Street, Suite 2600, San Francisco, California 94104, (415) 781-9700; or Hambrecht & Quist LLC, One Bush Street, San Francisco, California 94104, (415) 439-3300.

This press release contains forward-looking statements that are subject to risks and uncertainties that may cause the Company's actual results to differ materially. A full discussion of the Company's operations and financial condition, and specific factors that could cause the Company's actual performance to differ from current expectations, are discussed in the Company's SEC reports, including, but not limited to, the Company's Report on Form 10-Q for the quarter ended June 30, 1997 and Report on Form 10-K for the year ended December 31, 1996.

CONTACT: COR Therapeutics, Inc. Burns McClellan, Inc.

Laura A. Brege Lisa Burns

Jacquelyn A. Jeffries Jonathan M. Nugent

(650) 244-6893 (212) 213-0006